169 related articles for article (PubMed ID: 35790916)
1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
Provencio M; Cobo M; Rodriguez-Abreu D; Calvo V; Carcereny E; Cantero A; Bernabé R; Benitez G; Castro RL; Massutí B; Del Barco E; García Campelo R; Guirado M; Camps C; Ortega AL; González Larriba JL; Sánchez A; Casal J; Sala MA; Juan-Vidal O; Bosch-Barrera J; Oramas J; Dómine M; Trigo JM; Blanco R; Calzas J; Morilla I; Padilla A; Pimentao J; Sousa PA; Torrente M
BMC Cancer; 2022 Jul; 22(1):732. PubMed ID: 35790916
[TBL] [Abstract][Full Text] [Related]
2. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
[TBL] [Abstract][Full Text] [Related]
3. Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Martín-López J; Rojo F; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; de Alda LR; García JF; Salas C
J Clin Pathol; 2023 May; 76(5):327-332. PubMed ID: 34903610
[TBL] [Abstract][Full Text] [Related]
4. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
5. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
[TBL] [Abstract][Full Text] [Related]
6. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
[TBL] [Abstract][Full Text] [Related]
8. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
[TBL] [Abstract][Full Text] [Related]
10. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP; Groen HJM; Schuuring E; Aarts MJ; Damhuis RAM; Voorham QJM; ; Ligtenberg MJL; Grünberg K
Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
[TBL] [Abstract][Full Text] [Related]
11. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
[TBL] [Abstract][Full Text] [Related]
12. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
14. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
Nadler E; Vasudevan A; Wang Y; Ogale S
Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
[TBL] [Abstract][Full Text] [Related]
15. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
16. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Griesinger F; Eberhardt W; Nusch A; Reiser M; Zahn MO; Maintz C; Bernhardt C; Losem C; Stenzinger A; Heukamp LC; Büttner R; Marschner N; Jänicke M; Fleitz A; Spring L; Sahlmann J; Karatas A; Hipper A; Weichert W; Heilmann M; Sadjadian P; Gleiber W; Grah C; Waller CF; Reck M; Rittmeyer A; Christopoulos P; Sebastian M; Thomas M;
Lung Cancer; 2021 Feb; 152():174-184. PubMed ID: 33358484
[TBL] [Abstract][Full Text] [Related]
17. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
Lemmon CA; Zhou J; Hobbs B; Pennell NA
JCO Precis Oncol; 2023 Jan; 7():e2200294. PubMed ID: 36634300
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
Garrido P; de Castro J; Concha Á; Felip E; Isla D; López-Ríos F; Paz-Ares L; Ramírez J; Sanz J; Gómez JJ
Clin Transl Oncol; 2012 May; 14(5):338-49. PubMed ID: 22551539
[TBL] [Abstract][Full Text] [Related]
19. [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Belén Enguita A
Rev Esp Patol; 2023; 56(2):97-112. PubMed ID: 37061248
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
